RESUMO
Patients with coronavirus disease 2019 (COVID-19) present with multisystem signs and symptoms, including dermatologic manifestations. The recent literature has revealed that dermatologic manifestations of COVID-19 often are early onset and provide helpful cues to a timely diagnosis. We compiled the relevant emerging literature regarding the dermatologic manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) so that physicians can be aware of the various clinical cutaneous presentations in this time of high incidence of COVID-19.
Assuntos
COVID-19/fisiopatologia , Dermatopatias/fisiopatologia , Alopecia/fisiopatologia , Pérnio/fisiopatologia , Cianose/fisiopatologia , Toxidermias/fisiopatologia , Eritema Multiforme/fisiopatologia , Humanos , Livedo Reticular/fisiopatologia , Pitiríase Rósea/fisiopatologia , Púrpura/fisiopatologia , SARS-CoV-2 , Dermatopatias Vesiculobolhosas/fisiopatologia , Urticária/fisiopatologiaRESUMO
The severe acute respiratory syndrome coronavirus two (SARS-CoV-2), which causes the 2019 coronavirus disease (COVID-19), has infected patients worldwide. Physicians have increasingly identified cutaneous findings as a significant clinical manifestation of COVID-19. In this review, we describe the clinical presentation, onset, duration, associated symptoms, treatment, and outcome of cutaneous manifestations thus far reported to be related to COVID-19. We have included data from 63 studies and subdivided reported cutaneous manifestations into the categories of viral exanthem, urticarial, vesicular, chilblains/chilblains-like, non-chilblains vasculopathy-related, pityriasis rosea-like, erythema multiforme-like, Kawasaki/Kawasaki-like disease, and others. Physicians should be aware of the known common cutaneous manifestations of COVID-19 and future research is required to better understand the pathophysiology and prognosis of each COVID-19-related skin manifestation.
Assuntos
COVID-19/fisiopatologia , Dermatopatias/fisiopatologia , Pérnio/fisiopatologia , Eritema Multiforme/fisiopatologia , Exantema/fisiopatologia , Humanos , Síndrome de Linfonodos Mucocutâneos/fisiopatologia , Pitiríase Rósea/fisiopatologia , SARS-CoV-2 , Dermatopatias Vasculares/fisiopatologia , Dermatopatias Vesiculobolhosas/fisiopatologia , Síndrome de Resposta Inflamatória Sistêmica/fisiopatologia , Urticária/fisiopatologiaRESUMO
Angioedema without wheals (urticaria) represents a heterogeneous group of clinically indistinguishable diseases of hereditary or acquired etiology. Hereditary angioedema is a rare inherited condition leading to recurrent, sometimes life-threatening angioedema attacks in subcutaneous tissues and gastrointestinal and oropharyngeal mucosa dating back to childhood or adolescence. Most of these patients have mutations in the SERPING1 gene, causing either low C1 inhibitor production (hereditary angioedema with C1 inhibitor deficiency type I) or the production of dysfunctional C1 inhibitor (hereditary angioedema with C1 inhibitor deficiency type II). Hereditary angioedema with normal C1 inhibitor has been defined later. Although C1 inhibitor concentration and function are in the normal range, it leads to typical hereditary angioedema symptoms owing to mutations in FXII, PLG, ANGPT1, KNG1, and MYOF genes. Patients who exhibit none of these genetic mutations despite having a similar clinical presentation are classified as having unknown hereditary angioedema. Fewer than 1 in 10 patients with C1 inhibitor deficiency have acquired angioedema with C1 inhibitor deficiency. The clinical presentation is very similar to that of hereditary angioedema, making it difficult to distinguish these 2 conditions clinically. Unlike hereditary angioedema, there are no genetic mutations, and family history and symptoms tend to appear later in life. Acquired angioedema with C1 inhibitor deficiency is commonly associated with lymphoproliferative and autoimmune diseases. Angioedema attacks might start 1 year before the underlying disease in acquired angioedema with C1 inhibitor deficiency. Approximately half of the patients admitted to the hospital for acute angioedema are patients receiving angiotensin-converting enzyme (ACE) inhibitor therapy. Angioedema typically occurs on the lips, tongue, mouth, pharynx, and subglottic regions. Patients may require hospitalization and intensive care monitoring owing to airway involvement. Idiopathic histaminergic acquired angioedema may be diagnosed only when any possible causes of histaminergic angioedema are excluded (foods, drugs, animal dander, aeroallergens, insect stings, latex, and others), and the symptoms respond well to antihistamine treatment. Idiopathic nonhistaminergic acquired angioedema should be considered when all other types of recurrent angioedema have been ruled out and patients do not respond to high-dose antihistamines. The lack of a standard biochemical laboratory test for patients with idiopathic histaminergic acquired angioedema, idiopathic nonhistaminergic acquired angioedema, angiotensin-converting enzyme inhibitor-induced acquired angioedema, and hereditary angioedema with normal C1 inhibitor makes the diagnosis more challenging. Future efforts should focus on increasing awareness of all the rare types of angioedema among physicians and developing more straightforward and more accessible diagnostic methods.
Assuntos
Angioedema/diagnóstico , Angioedemas Hereditários/diagnóstico , Urticária/classificação , Angioedema/fisiopatologia , Angioedemas Hereditários/fisiopatologia , Bradicinina/fisiologia , Histamina/fisiologia , Humanos , Urticária/fisiopatologiaRESUMO
OBJECTIVES: To describe the emergency department (ED) triage of anaphylaxis patients based on the Emergency Severity Index (ESI), assess the association between ESI triage level and ED epinephrine administration, and determine characteristics associated with lower acuity triage ESI assignment (levels 3 and 4). METHODS: We conducted a cohort study of adult and pediatric anaphylaxis patients between September 2010 and September 2018 at an academic ED. Patient characteristics and management were compared between Emergency Severity Index (ESI) triage level 1 or 2 versus levels 3 or 4 using logistic regression analysis. We adhered to STROBE reporting guidelines. RESULTS: A total of 1090 patient visits were included. There were 26 (2%), 515 (47%), 489 (45%), and 60 (6%) visits that were assigned an ESI triage level of 1, 2, 3, and 4, respectively. Epinephrine was administered in the ED to 53% of patients triaged ESI level 1 or 2 and to 40% of patients triaged ESI level 3 or 4. Patients who were assigned a lower acuity ESI level of 3 or 4 had a longer median time from ED arrival to epinephrine administration compared to those with a higher acuity ESI level of 1 or 2 (28 min compared to 13 min, p < .001). A lower acuity ESI level was more likely to be assigned to visits with a chief concern of hives, rash, or pruritus (OR 2.33 [95% CI, 1.20-4.53]) and less likely to be assigned to visits among adults (OR, 0.43 [0.31-0.60]), patients who received epinephrine from emergency medical services (OR 0.56 [0.38-0.82]), presented with posterior pharyngeal or uvular angioedema (OR, 0.56 [0.38-0.82]), hypoxemia (OR, 0.34 [0.18-0.64]), or increased heart (OR 0.83 [0.73-0.95]) or respiratory (OR 0.70 [0.60-0.82]) rates. CONCLUSION: Patients triaged to lower acuity ESI levels experienced delays in ED epinephrine administration. Adult and pediatric patients with skin-related chief concerns were more likely to be to be assigned lower acuity ESI levels. Further studies are needed to identify interventions that will improve ED anaphylaxis triage.
Assuntos
Anafilaxia/diagnóstico , Serviço Hospitalar de Emergência , Gravidade do Paciente , Tempo para o Tratamento/estatística & dados numéricos , Triagem , Centros Médicos Acadêmicos , Adolescente , Adulto , Fatores Etários , Anafilaxia/tratamento farmacológico , Anafilaxia/fisiopatologia , Angioedema/fisiopatologia , Criança , Pré-Escolar , Estudos de Coortes , Serviços Médicos de Emergência , Epinefrina/uso terapêutico , Feminino , Humanos , Hipóxia/fisiopatologia , Lactente , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Razão de Chances , Faringe , Prurido/fisiopatologia , Índice de Gravidade de Doença , Simpatomiméticos/uso terapêutico , Taquicardia/fisiopatologia , Taquipneia/fisiopatologia , Urticária/fisiopatologia , Úvula , Adulto JovemRESUMO
Osteoporosis (OP) is defined as a generalized skeletal disease characterized by low bone mass and an alteration of the microarchitecture that lead to an increase in bone fragility and, therefore, an increased risk of fractures. It must be considered today as a true public health problem and the most widespread metabolic bone disease that affects more than 200 million people worldwide. Under physiological conditions, there is a balance between bone formation and bone resorption necessary for skeletal homeostasis. In pathological situations, this balance is altered in favor of osteoclast (OC)-mediated bone resorption. During chronic inflammation, the balance between bone formation and bone resorption may be considerably affected, contributing to a net prevalence of osteoclastogenesis. Skin diseases are the fourth cause of human disease in the world, affecting approximately one third of the world's population with a prevalence in elderly men. Inflammation and the various associated cytokine patterns are the basis of both osteoporosis and most skin pathologies. Moreover, dermatological patients also undergo local or systemic treatments with glucocorticoids and immunosuppressants that could increase the risk of osteoporosis. Therefore, particular attention should be paid to bone health in these patients. The purpose of the present review is to take stock of the knowledge in this still quite unexplored field, despite the frequency of such conditions in clinical practice.
Assuntos
Osteoporose/complicações , Dermatopatias/complicações , Vesícula/complicações , Vesícula/fisiopatologia , Remodelação Óssea/fisiologia , Citocinas/fisiologia , Dermatite Atópica/complicações , Dermatite Atópica/fisiopatologia , Fármacos Dermatológicos/efeitos adversos , Humanos , Modelos Biológicos , Osteoporose/induzido quimicamente , Osteoporose/fisiopatologia , Psoríase/complicações , Psoríase/fisiopatologia , Envelhecimento da Pele/fisiologia , Dermatopatias/tratamento farmacológico , Dermatopatias/fisiopatologia , Neoplasias Cutâneas/complicações , Neoplasias Cutâneas/fisiopatologia , Urticária/complicações , Urticária/fisiopatologia , Vitamina D/fisiologiaRESUMO
This is a case of a patient who presented with an urticarial rash 48 hours before developing symptoms of fever and a continuous cough. She subsequently developed angioedema of her lips and hands before testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Urticarial rashes occurring 48 hours before other symptoms of COVID-19 infection have been documented. This case demonstrates the importance of heightened awareness that not all urticarial rashes represent spontaneous urticaria and as a consequence, this may result in misdiagnosis and ultimately delayed diagnosis. This is the first reported case in the literature of urticaria with angioedema as a prodromal phenomenon of COVID-19.
Assuntos
Angioedema , Clorfeniramina/administração & dosagem , Infecções por Coronavirus , Pandemias , Pneumonia Viral , Prednisona/administração & dosagem , Terfenadina/análogos & derivados , Urticária , Angioedema/diagnóstico , Angioedema/etiologia , Angioedema/fisiopatologia , Antialérgicos/administração & dosagem , Betacoronavirus/isolamento & purificação , COVID-19 , Infecções por Coronavirus/complicações , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/fisiopatologia , Diagnóstico Diferencial , Feminino , Humanos , Pessoa de Meia-Idade , Pneumonia Viral/complicações , Pneumonia Viral/diagnóstico , Pneumonia Viral/fisiopatologia , Sintomas Prodrômicos , SARS-CoV-2 , Terfenadina/administração & dosagem , Resultado do Tratamento , Urticária/diagnóstico , Urticária/etiologia , Urticária/fisiopatologiaAssuntos
COVID-19/complicações , Dermatopatias Virais/diagnóstico , Urticária/virologia , COVID-19/diagnóstico , COVID-19/virologia , Humanos , SARS-CoV-2/isolamento & purificação , Dermatopatias Virais/imunologia , Dermatopatias Virais/fisiopatologia , Urticária/diagnóstico , Urticária/fisiopatologiaAssuntos
COVID-19/fisiopatologia , Família , Urticária/fisiopatologia , Ageusia/fisiopatologia , Anosmia/fisiopatologia , COVID-19/patologia , Calafrios/fisiopatologia , Tontura/fisiopatologia , Feminino , Antagonistas dos Receptores Histamínicos/uso terapêutico , Humanos , México , Pessoa de Meia-Idade , Urticária/tratamento farmacológico , Urticária/patologia , Adulto JovemRESUMO
: Wine, beer, liquor, and spirits are widely consumed in many cultures across the globe, and for some individuals, ingestion, cutaneous contact, or other exposure can lead to dermatologic findings. However, there currently exist no comprehensive reviews on alcohol-related dermatitis. Herein, we will provide an overview of alcohol-related dermatitis and contact urticaria, including the epidemiology and clinical manifestations, potential allergens found in alcoholic beverages, testing approaches, and strategies for allergen avoidance.
Assuntos
Bebidas Alcoólicas/efeitos adversos , Dermatite Alérgica de Contato/epidemiologia , Urticária/epidemiologia , Bálsamos/efeitos adversos , Cerveja/efeitos adversos , Cromo/efeitos adversos , Citrus/efeitos adversos , Cobalto/efeitos adversos , Dermatite/epidemiologia , Dermatite/fisiopatologia , Dermatite/terapia , Dermatite Alérgica de Contato/etiologia , Dermatite Alérgica de Contato/fisiopatologia , Dermatite Alérgica de Contato/terapia , Conservantes de Alimentos/efeitos adversos , Ouro/efeitos adversos , Humanos , Hipersensibilidade Tardia/epidemiologia , Hipersensibilidade Tardia/etiologia , Hipersensibilidade Tardia/fisiopatologia , Hipersensibilidade Tardia/terapia , Hipersensibilidade Imediata/epidemiologia , Hipersensibilidade Imediata/etiologia , Hipersensibilidade Imediata/fisiopatologia , Hipersensibilidade Imediata/terapia , Isotiocianatos/efeitos adversos , Níquel/efeitos adversos , Propilenoglicol/efeitos adversos , Sulfitos/efeitos adversos , Urticária/etiologia , Urticária/fisiopatologia , Urticária/terapia , Vinho/efeitos adversosRESUMO
Urticaria is a common skin disorder characterized by the rapid appearance and disappearance of local skin edema and flares with itching. It is characterized by various macroscopic skin eruptions unique to patients and/or subtypes of urticaria with respect to shape, size, color, and/or duration of eruptions. Nevertheless, the mechanism underlying multifarious eruptions in urticaria is largely unknown. The eruptions are believed to be evoked by histamine release from mast cells in the skin. However, the majority of visible characteristics of urticaria cannot be explained by a simple injection of histamine to the skin. To explain the multifarious eruptions of urticaria, we developed a single reaction-diffusion model suggesting the self-activation and self-inhibition regulation of histamine release from mast cells. Using the model, we found that various geometrical shapes of eruptions typically observed in patients can be explained by the model parameters and randomness or strength of the initial stimuli to mast cells. Furthermore, we verified that the wheal-expanding speed of urticaria, which is shown to be much smaller than that of the intradermal injection experimental system may be explained by our model and a simple diffusion equation. Our study suggests that the simple reaction-diffusion dynamics, including the independent self-activating and -inhibitory regulation of histamine release, may account for the essential mechanism underlying the formation of multifarious eruptions in urticaria.
Assuntos
Modelos Biológicos , Urticária , Biologia Computacional , Histamina/metabolismo , Liberação de Histamina/fisiologia , Humanos , Mastócitos/metabolismo , Pele/metabolismo , Pele/patologia , Pele/fisiopatologia , Urticária/metabolismo , Urticária/patologia , Urticária/fisiopatologiaRESUMO
OBJECTIVE: Little is known regarding food anaphylaxis in infancy. We aimed to describe specificities of food anaphylaxis in infants (≤12 months) as compared to preschool children (1-6 years). METHODS: We conducted a retrospective study of all food anaphylaxis cases recorded by the Allergy Vigilance Network from 2002 to 2018, in preschool children focusing on infants. RESULTS: Of 1951 food anaphylaxis reactions, 61 (3%) occurred in infants and 386 (20%) in preschool children. Two infants had two anaphylaxis reactions; thus, we analyzed data among 59 infants (male: 51%; mean age: 6 months [SD: 2.9]); 31% had a history of atopic dermatitis, 11% of previous food allergy. The main food allergens were cow's milk (59%), hen's egg (20%), wheat (7%) and peanut (3%) in infants as compared with peanut (27%) and cashew (23%) in preschool children. Anaphylaxis occurred in 28/61 (46%) cases at the first cow's milk intake after breastfeeding discontinuation. Clinical manifestations were mainly mucocutaneous (79%), gastrointestinal (49%), respiratory (48%) and cardiovascular (21%); 25% of infants received adrenaline. Hives, hypotension and neurologic symptoms were more likely to be reported in infants than in preschool children (P = .02; P = .004; P = .002, respectively). Antihistamines and corticosteroids were more often prescribed in preschool children than in infants (P = .005; P = .025, respectively). CONCLUSION: Our study found that in infants presenting with their first food allergy, in a setting with a high rate of infant formula use, the most predominant trigger was cow's milk. As compared to older preschool children, hives, hypotonia and hypotension were more likely to be reported in infants. We believe that this represents a distinct food anaphylaxis phenotype that can further support developing the clinical anaphylaxis criteria in infants.
Assuntos
Distribuição por Idade , Anafilaxia/epidemiologia , Hipersensibilidade Alimentar/epidemiologia , Anacardium , Anafilaxia/etiologia , Anafilaxia/fisiopatologia , Angioedema/fisiopatologia , Pré-Escolar , Tosse/fisiopatologia , Choro , Dispneia/fisiopatologia , Hipersensibilidade a Ovo/complicações , Hipersensibilidade a Ovo/epidemiologia , Hipersensibilidade a Ovo/fisiopatologia , Feminino , Hipersensibilidade Alimentar/complicações , Hipersensibilidade Alimentar/fisiopatologia , Humanos , Hipotensão/fisiopatologia , Lactente , Edema Laríngeo/fisiopatologia , Masculino , Hipersensibilidade a Leite/complicações , Hipersensibilidade a Leite/epidemiologia , Hipersensibilidade a Leite/fisiopatologia , Hipotonia Muscular/fisiopatologia , Hipersensibilidade a Noz/complicações , Hipersensibilidade a Noz/epidemiologia , Hipersensibilidade a Noz/fisiopatologia , Hipersensibilidade a Amendoim/complicações , Hipersensibilidade a Amendoim/epidemiologia , Hipersensibilidade a Amendoim/fisiopatologia , Prurido/fisiopatologia , Agitação Psicomotora/fisiopatologia , Sons Respiratórios/fisiopatologia , Estudos Retrospectivos , Convulsões/fisiopatologia , Urticária/fisiopatologia , Vômito/fisiopatologia , Hipersensibilidade a Trigo/complicações , Hipersensibilidade a Trigo/epidemiologia , Hipersensibilidade a Trigo/fisiopatologiaRESUMO
Introduction: Food-dependent, exercise-induced anaphylaxis (FDEIA) is a rare type of anaphylaxis with a growing incidence. Although the precise mechanism by which the patient reacts only in a combination of a culprit food and cofactors are not currently understood, many advances in diagnosis and management have been made since their first description. Areas covered: A literature search in PubMed was performed to review the diagnosis and management of FDEIA. Clinicians should have a high level of suspicion for identification of the culprit foods and the cofactors involved. Component-resolved diagnosis and more accurate provocation tests have revolutionized the diagnosis accuracy. Management is not easy and involves educating the patient to evict the combination of exposure to the culprit foods and the cofactors that elicit anaphylaxis, and how to act and treat if a reaction occurs. Expert opinion: FDEIA is currently misdiagnosed and the authors believe that there are many FDEIA patients labelled as idiopathic anaphylaxis with unnecessary evictions and with a poor quality of life because of the fear of an imminent reaction. Due to recent advances in diagnostic tools and the use of monoclonal antibodies for prophylaxis in persistent cases, FDEIA can have a better prognosis improving the quality of life of the patients and their families.
Assuntos
Alérgenos/imunologia , Anafilaxia/imunologia , Exercício Físico/fisiologia , Hipersensibilidade Alimentar/imunologia , Anafilaxia/diagnóstico , Anafilaxia/terapia , Broncodilatadores/administração & dosagem , Epinefrina/administração & dosagem , Fadiga/diagnóstico , Fadiga/imunologia , Fadiga/fisiopatologia , Hipersensibilidade Alimentar/fisiopatologia , Humanos , Testes Cutâneos/métodos , Urticária/diagnóstico , Urticária/imunologia , Urticária/fisiopatologiaRESUMO
Strongyloides stercoralis, a worldwide-distributed soil-transmitted helminth, causes chronic infection which may be life threatening. Limitations of diagnostic tests and nonspecificity of symptoms have hampered the estimation of the global morbidity due to strongyloidiasis. This work aimed at assessing S. stercoralis-associated morbidity through a systematic review and meta-analysis of the available literature. MEDLINE, Embase, CENTRAL, LILACS, and trial registries (WHO portal) were searched. The study quality was assessed using the Newcastle-Ottawa scale. Odds ratios (ORs) of the association between symptoms and infection status and frequency of infection-associated symptoms were calculated. Six articles from five countries, including 6,014 individuals, were included in the meta-analysis-three were of low quality, one of high quality, and two of very high quality. Abdominal pain (OR 1.74 [CI 1.07-2.94]), diarrhea (OR 1.66 [CI 1.09-2.55]), and urticaria (OR 1.73 [CI 1.22-2.44]) were associated with infection. In 17 eligible studies, these symptoms were reported by a large proportion of the individuals with strongyloidiasis-abdominal pain by 53.1% individuals, diarrhea by 41.6%, and urticaria by 27.8%. After removing the low-quality studies, urticaria remained the only symptom significantly associated with S. stercoralis infection (OR 1.42 [CI 1.24-1.61]). Limitations of evidence included the low number and quality of studies. Our findings especially highlight the appalling knowledge gap about clinical manifestations of this common yet neglected soil-transmitted helminthiasis. Further studies focusing on morbidity and risk factors for dissemination and mortality due to strongyloidiasis are absolutely needed to quantify the burden of S. stercoralis infection and inform public health policies.
Assuntos
Dor Abdominal/fisiopatologia , Diarreia/fisiopatologia , Strongyloides stercoralis/patogenicidade , Estrongiloidíase/epidemiologia , Estrongiloidíase/fisiopatologia , Urticária/fisiopatologia , Dor Abdominal/parasitologia , África/epidemiologia , Animais , Ásia/epidemiologia , Austrália/epidemiologia , Diarreia/parasitologia , Feminino , Humanos , Japão/epidemiologia , Masculino , Razão de Chances , Fatores de Risco , Solo/parasitologia , Strongyloides stercoralis/fisiologia , Estrongiloidíase/parasitologia , Estrongiloidíase/transmissão , Urticária/parasitologiaRESUMO
BACKGROUND: The daily diary Urticaria Activity Score (UAS) and its weekly score (UAS7) are widely used to assess signs and symptoms in patients with chronic spontaneous urticaria (CSU). The objective of this study was to assess the psychometric properties of a Spanish version of the once-daily UAS. METHODS: Observational study in patients ≥18 years old receiving usual care for CSU (daily or almost daily occurrence of generalized hives or angioedema for ≥6 weeks). Patients were included consecutively and completed the UAS, EQ-5D, and the Chronic Urticaria Quality of Life scale (CU-Q2oL) at two study visits 6 weeks apart. On each occasion, the UAS was completed once-daily for 7 consecutive days to be able to calculate the UAS7 score. Psychometric properties of reliability, construct validity, and responsiveness were assessed. The Minimal Important Difference (MID) was estimated for the UAS7 using anchor- and distribution-based approaches. RESULTS: Data from 166 patients was available for analysis (mean age 49 years, 65.7% female). Floor (5.4% of patients with the lowest possible score) and ceiling (1.2%) effects were low; 15% of patients had missing values. Internal consistency and test-retest reliability were good (Cronbach's alpha of 0.83 and an ICC of 0.84, respectively). Convergent validity was demonstrated through the pattern of correlations with the EQ-5D and CU-Q2oL and known groups' validity was demonstrated by the instrument's ability to discriminate between patients with different overall levels of urticaria severity, with between-group effect-sizes (ES) ranging from 0.36 to 1.19. The UAS7 proved responsive to change with effect sizes ranging from 0.3 to 1.52 in patients reporting improvement or deterioration in overall urticaria status. The MID for the UAS7 score was estimated at 7-8 points, on a scale of 0-42. CONCLUSIONS: The Spanish version of the UAS score has demonstrated a robust psychometric performance in patients with CSU managed in conditions of usual care. It can therefore be considered a suitable instrument to assess disease activity in clinical practice in Spanish-speaking patients. The Spanish version's reliability and validity are similar to those reported for other language versions of the once- and twice-daily variants of the UAS.
Assuntos
Medidas de Resultados Relatados pelo Paciente , Qualidade de Vida , Urticária/psicologia , Adulto , Idoso , Doença Crônica/psicologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Psicometria , Reprodutibilidade dos Testes , Índice de Gravidade de Doença , Espanha , Traduções , Urticária/fisiopatologiaRESUMO
BACKGROUND: The rate of true vaccine allergy is unknown. Children with potential IgE-mediated adverse events following immunization (AEFI) should undergo allergy investigation that may include skin testing or challenge. Previous protocols tend to be highly conservative and often suggest invasive testing for all, a practice not evidence based, technically difficult, and unpleasant in children. It has more recently been suggested that skin testing may be restricted to those with allergic-like events within the first hour and those with a history of anaphylaxis. OBJECTIVE: We aimed to describe the outcome of vaccine skin testing and challenge in children referred to a tertiary pediatric hospital with a potential IgE-mediated AEFI. The secondary aim was to identify any significant risk factors for vaccine allergy. METHODS: A retrospective review of all children (<18 years) who underwent vaccine skin testing (skin prick testing or intradermal testing [IDT]) or challenge over a 5-year period (May 1, 2011, to April 30, 2016) at the Royal Children's Hospital Melbourne is presented. RESULTS: There were 95 admissions in 73 children. Eight percent (6 of 73) of children had confirmed vaccine allergy (positive skin testing or challenge to the index vaccination). Two had positive IDT to a suspect vaccine but challenge negative to an alternative brand vaccine. Two had negative IDT but subsequent positive challenge and two had immediate urticaria on challenge without prior skin testing. All children in the positive group either had index reaction within 15 minutes of vaccination or had history consistent with anaphylaxis. CONCLUSIONS: The vast majority of children (92%) presenting with a potential IgE-mediated AEFI are able to tolerate challenge to a suspect vaccine without reaction. We present our investigation protocol recommending skin testing in all children with anaphylaxis and challenge with a suspect vaccine if negative testing or previous nonanaphylactic potential IgE-mediated AEFI.
Assuntos
Hipersensibilidade Imediata/diagnóstico , Fatores Imunológicos/efeitos adversos , Vacinas/efeitos adversos , Adolescente , Anafilaxia/diagnóstico , Anafilaxia/etiologia , Anafilaxia/fisiopatologia , Angioedema/diagnóstico , Angioedema/etiologia , Angioedema/fisiopatologia , Austrália , Criança , Pré-Escolar , Vacina contra Difteria, Tétano e Coqueluche/efeitos adversos , Vacinas contra Difteria, Tétano e Coqueluche Acelular/efeitos adversos , Feminino , Vacinas Anti-Haemophilus/efeitos adversos , Vacinas contra Hepatite A/efeitos adversos , Vacinas contra Hepatite B/efeitos adversos , Hospitais Pediátricos , Humanos , Hipersensibilidade Imediata/etiologia , Hipersensibilidade Imediata/fisiopatologia , Lactente , Vacinas contra Influenza/efeitos adversos , Testes Intradérmicos , Masculino , Vacina contra Sarampo-Caxumba-Rubéola/efeitos adversos , Vacinas contra Papillomavirus/efeitos adversos , Vacinas Pneumocócicas/efeitos adversos , Vacina Antipólio de Vírus Inativado/efeitos adversos , Polissacarídeos Bacterianos/efeitos adversos , Estudos Retrospectivos , Vacinas contra Rotavirus/efeitos adversos , Testes Cutâneos , Centros de Atenção Terciária , Fatores de Tempo , Vacinas Tíficas-Paratíficas/efeitos adversos , Urticária/diagnóstico , Urticária/etiologia , Urticária/fisiopatologia , Vacinas Atenuadas/efeitos adversos , Vacinas Combinadas/efeitos adversosRESUMO
BACKGROUND: Quality of life, which is impaired in patients with chronic spontaneous urticaria (CSU), is influenced by comorbid mental disorders. Headaches could be another comorbid mental disorder that affects quality of life in children with CSU. OBJECTIVES: To investigate the effect of headaches on urticaria symptoms, disease activity and quality of life in children with CSU. METHODS: A total of 83 patients with CSU were enrolled in the study and were separated into two groups as those with or without headache. Demographic and clinical characteristics were studied with the Urticaria Activity Score (UAS7), Urticaria Control test (UCT) and Chronic Urticaria Quality of Life Questionnaire (CU-Q2QoL). The headache questionnaire designed according to the Department of International Classification of Headache Disorders, second edition (ICHD-II) was used and VAS (Visual Analogue Scale) and NRS (Numerical Rating Scale) were used to assess the pain measurement. In patients diagnosed with migraine, the paediatric Migraine Disability Assessment Scale (PedMIDAS) was applied. RESULTS: CU-QoL total scores were significantly higher in patients with CSU with headache than in those without headache (p=0.015). In the five domains of CU-QoL, impact of daily life activities domain and sleep problems domain had higher scores in CSU with headache (p=0.008, 0.028, respectively). There was no significant relationship between UCT, UAS and CU-QoL and headache severity (p<0.05). No differences were found between the groups in respect of duration of urticaria, UAS7 and UCT. CONCLUSION: Headache may be an important factor that affects and impairs quality of life in children with chronic urticaria.
Assuntos
Cefaleia/fisiopatologia , Urticária/fisiopatologia , Adolescente , Criança , Doença Crônica , Estudos Transversais , Feminino , Cefaleia/epidemiologia , Humanos , Masculino , Medição da Dor , Qualidade de Vida , Índice de Gravidade de Doença , Inquéritos e Questionários , Turquia/epidemiologia , Urticária/epidemiologiaRESUMO
Water-related dermatoses are a spectrum of diseases that are associated with water exposure. They result either from the direct influence of water or after injury from water inhabitants. In this review, clinical entities that manifest after water exposure (aquagenic pruritus, aquagenic urticaria, and aquagenic wrinkling of the palms) will be discussed with particular focus on the reported pathogenesis. Aquatic organisms and activities can be linked to cutaneous injuries that require identification and distinct management. Marine and freshwater dermatoses were summarized to provide physicians with easy access to the causative organism, method of injury, and appropriate management.